immunoglobulin G1- kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody (Firastotug)
Advanced/Metastatic Solid Tumors
Adagene Incmonoclonal_antibodyPhase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Advanced/Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ADG 106 Adagene Inc | Phase 1/2 | B |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
Muzastotug Adagene Inc | Phase 1/2 | CCC |
Hrs-6719 Shandong Suncadia Medicine Co., Ltd. | Phase 1/2 | CC |
Mcla-158 Merus B.V. | Phase 1/2 | CC |
View all 33 →
Same molecule, other indications
immunoglobulin G1- kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody (Firastotug) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →